LYA914
LYA914 is an orally active AR/AR-V7 PROTAC degrader. LYA914 targets the proteolytic degradation of the conserved DNA binding domain (DBD) of the androgen receptor (AR). LYA914 exhibits potent antiproliferative effects in Enzalutamide (HY-70002)-insensitive/resistant cells. LYA914 inhibits tumor growth in VCaP/LNCaP tumor mouse models. LYA914 can be used to study castration-resistant prostate cancer (CRPC).
(Pink: AR-DBD ligand (HY-175456); Blue: Cereblon ligand (HY-14658); Black: linker (HY-175458)).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C38H43F2N7O5S
- Masse moléculaire:747.85
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform PROTACs
More
Activité biologique
|
Cereblon |
LYA914 (1-10 μM) degrades AR protein in LNCaP cells, 22Rv1 cells with degradation rates of 40.2% and 39.1% at 1 μM, and 82.5% and 84.5% at 10 μM, degrades AR-V7 protein in 22Rv1 cells with degradation rates of 37.4% at 1 μM, and 83.9% at 10 μM[1].
LYA914 (0.01-10 μM, 24 h) enhances the binding of CRBN and AR, and induces the degradation of AR and AR-V7, the DC50s in 22RV1 cells are 0.41 and 0.83 μM, respectively, and the DC50s in vcaP cells are 0.32 and 0.33 μM, respectively, also induces the degradation of AR and AR-V7 in LNCaP cells[1].
LYA914 (24 h) inhibits AR/AR-V7-driven transcriptional activity in overexpressed AR or AR-V7 and the reporter plasmid in 293T cells, with IC50s of 0.19 and 1.29 μM[1].
LYA914 (1-3 μM, 48 h) shows a significant blockade on the AR/AR-V7 signaling pathway by transcriptional inhibition in 22Rv1 cells[1].
LYA914 (5 days) shows antiproliferation activity in LNCaP, VCaP, 22Rv1 cells, with IC50s of 1.21, 1.6, 1.15 μM, shows low cytotoxicity against HL-7702 cells[1].
LYA914 (6 days) remains the antiproliferative effects against LNCaP-EN and VCaP-EN cells with Enzalutamide (HY-70002) exposure, with IC50s of 4.12 and 1.66 μM[1].
LYA914 (24 h) shows significant inhibition on the transcriptional activity of HEK293T cells with AR reporter plasmids are cotransfected with AR (F876L) or AR (W741L) plasmids, respectively, with IC50s of 1.29 and 0.53 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:22Rv1, VCaP and LNCaP cells
-
Concentration:0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM
-
Incubation Time:0 h, 0.167 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 9 h, 11 h, 13 h, 24 h
-
Result:Induced AR and AR-V7 protein degradation with degradation began at 2 h and reached the maximum level after 13 h, degradation occurred at 6 h and reached maximum degradation at 24 h in AR-positive LNCaP cells.
-
Cell Line:22Rv1 cells
-
Concentration:1 μM, 3 μM
-
Incubation Time:48 h
-
Result:Down-regulated the expression of AR targets such as FKBP5, PSA, and TMPRSS2, and AR-V7 targets such as CCNA2, CDC20, and AKT1.
LYA914 (10-30 mg/kg, p.o., once a day, 16 days) exhibits tumor growth inhibition activity, with particularly notable oral efficacy in the VCaP xenograft model[1].
LYA914 (30-60 mg/kg, p.o., once a day, 14 days) shows no signs of toxicity and is well tolerated in ICR mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LNCaP (1 × 107) tumor NOD SCID mice (6 weeks old) model[1]
-
Dosage:30 and 100 mg/kg
-
Administration:i.p., once a day, 3 weeks
-
Result:Inhibited tumor growth, the tumor growth inhibition (TGI) rate reaches 83.6% at 100 mg/kg, reduces AR protein levels.
-
Animal Model:VCaP (1 × 107) tumor NOD SCID mice (6 weeks old) model[1]
-
Dosage:10 and 30 mg/kg
-
Administration:p.o., once a day, 16 days
-
Result:Inhibited tumor growth, the tumor growth inhibition (TGI) rate reaches 44.5% at 30 mg/kg.
-
Animal Model:ICR mice (6 weeks old) model[1]
-
Dosage:30 and 60 mg/kg
-
Administration:p.o., once a day, 14 days
-
Result:Had no obvious weight loss or organ damage, had no change of physiological morphology and function of each organ.
Chemical Information
-
Masse moléculaire 747.85
-
Formule C38H43F2N7O5S
-
SMILES
O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(N4CCC(CN5CCC(N6CCN(C7=NC(C8=CC=C(F)C(F)=C8OC)=CS7)CC6)CC5)CC4)=C3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LYA914 Related Classifications
HY-175455 Related Classifications
Powered by Bioz